Abstract: Beijing QL Biopharm, a China-based biopharmaceutical company, is looking to raise via a Hong Kong listing. Jefferies and Huatai are the joint sponsors. In this note, we look at the company's one Phase III core product, zovaglutide (ZT002). We also look at the company's pre-IPO investors and management team.
IMEIK TECHNOLOGY DEVELOPMENT
Interested in the full report? Get in touch with our team.